Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy.
Strongin A, Yovino S, Taylor R, Wolf J, Cullen K, Zimrin A, Strome S, Regine W, Suntharalingam M. Strongin A, et al. Among authors: strome s. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1823-30. doi: 10.1016/j.ijrobp.2010.10.053. Epub 2011 May 5. Int J Radiat Oncol Biol Phys. 2012. PMID: 21549516
Oropharyngeal cancer as a driver of racial outcome disparities in squamous cell carcinoma of the head and neck: 10-year experience at the University of Maryland Greenebaum Cancer Center.
Zandberg DP, Liu S, Goloubeva O, Ord R, Strome SE, Suntharalingam M, Taylor R, Morales RE, Wolf JS, Zimrin A, Lubek JE, Schumaker LM, Cullen KJ. Zandberg DP, et al. Among authors: strome se. Head Neck. 2016 Apr;38(4):564-72. doi: 10.1002/hed.23933. Epub 2015 Jun 30. Head Neck. 2016. PMID: 25488341 Free PMC article.
Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck.
Suntharalingam M, Kwok Y, Goloubeva O, Parekh A, Taylor R, Wolf J, Zimrin A, Strome S, Ord R, Cullen KJ. Suntharalingam M, et al. Among authors: strome s. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1845-50. doi: 10.1016/j.ijrobp.2011.02.062. Epub 2011 May 19. Int J Radiat Oncol Biol Phys. 2012. PMID: 21601372 Free PMC article. Clinical Trial.
Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma.
Voskens CJ, Sewell D, Hertzano R, DeSanto J, Rollins S, Lee M, Taylor R, Wolf J, Suntharalingam M, Gastman B, Papadimitriou JC, Lu C, Tan M, Morales R, Cullen K, Celis E, Mann D, Strome SE. Voskens CJ, et al. Among authors: strome se. Head Neck. 2012 Dec;34(12):1734-46. doi: 10.1002/hed.22004. Epub 2012 Jan 27. Head Neck. 2012. PMID: 22287423 Free PMC article.
A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).
Zandberg DP, Rollins S, Goloubeva O, Morales RE, Tan M, Taylor R, Wolf JS, Schumaker LM, Cullen KJ, Zimrin A, Ord R, Lubek JE, Suntharalingam M, Papadimitriou JC, Mann D, Strome SE, Edelman MJ. Zandberg DP, et al. Among authors: strome se. Cancer Immunol Immunother. 2015 Mar;64(3):367-79. doi: 10.1007/s00262-014-1640-x. Epub 2014 Dec 24. Cancer Immunol Immunother. 2015. PMID: 25537079 Free PMC article. Clinical Trial.
Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients.
Settle K, Posner MR, Schumaker LM, Tan M, Suntharalingam M, Goloubeva O, Strome SE, Haddad RI, Patel SS, Cambell EV 3rd, Sarlis N, Lorch J, Cullen KJ. Settle K, et al. Among authors: strome se. Cancer Prev Res (Phila). 2009 Sep;2(9):776-81. doi: 10.1158/1940-6207.CAPR-09-0149. Epub 2009 Jul 29. Cancer Prev Res (Phila). 2009. PMID: 19641042 Free PMC article. Clinical Trial.
247 results